Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio.

Teva stock jumped early Wednesday on better-than-expected third-quarter metrics and a sales guidance hike for Austedo.

Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong sales of its trio branded drugs to treat migraines, Huntington's disease and schizophrenia.

For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC.

Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding 41.3 million Teva shares valued at $834.2 million.

TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) --  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows:

More than half a million bottles of Prazosin Hydrochloride have been recalled over high levels of a chemical compound that could cause cancer, the FDA said.

Added 4,306,363 Teva shares, an estimated $75.64 million trade based on the average quarterly price for Q3 2025 Transaction represents a 0.68% increase in reportable U.S. equity assets under management as of Q3 2025. Post-trade: 37,696,690 shares valued at $761.46 million as of Q3 2025.